Company intelligence / Profile preview
iCeutica
King of Prussia, Pennsylvania, United Statesiceutica.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Other
01
Overview
iCeutica developed a proprietary nanotechnology platform—SoluMatrix Fine Particle Technology—to reformulate existing drugs or new chemical entities into submicron particles. This approach improves bioavailability, enables lower dosing, and can reduce side effects. Four FDA-approved prescription drugs use this technology—Zorvolex™, Tivorbex™, Vivlodex™ for pain/inflammation and Yonsa® for prostate cancer. The company also has several pipeline products in development with partners but does not publicly disclose all details.
- Therapeutic areas
- OncologyPulmonologyImmunologyNeurology
- Modalities
- Small moleculeNanoparticle
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Multiple pharmaceutical partnerships for product co-development and commercialization
Beyond the preview
Go deeper on iCeutica.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iCeutica.